Results 51 to 60 of about 5,297,540 (313)

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch, A Hurtado, A Noske, AA Lazar, AC Wolff, Andre Robidoux, BM Müller, Bruno V Sinn, C Denkert, Carsten Denkert, Christine Solbach, CK Osborne, D Slamon, DG Altman, DJ Dabbs, EA Perez, EH Romond, FL Baehner, G Hennig, G Konecny, G Pentheroudakis, G von Minckwitz, G von Minckwitz, G von Minckwitz, Gunter von Minckwitz, H Joensuu, Hans Tesch, I Pinhel, J Baselga, J Baselga, Jan C Brase, Jens Huober, Judith Prinzler, K Bohmann, Keyur Mehta, Knut Engels, L Gianni, L Gianni, LM McShane, M Bonetti, M Dowsett, M Dowsett, M Filipits, M Untch, M Untch, M Untch, M Untch, Martin-Leo Hansmann, Mattea Reinisch, ME Hammond, Michael Untch, MJ Piccart-Gebhart, MP Fereshteh, PC Roche, Peter A Fasching, Ralf Kronenwett, S Johnston, S Paik, S Paik, Sibylle Loibl, Silvia Darb-Esfahani, T Lahusen, W Zhao   +62 more
core   +1 more source

IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.

Journal of Thoracic Oncology, 2020
Currently there is no established guidance on how to process and evaluate resected lung cancer specimens following neoadjuvant therapy in the setting of clinical trials and clinical practice.
W. Travis, S. Dacic, I. Wistuba, L. Sholl, P. Adusumilli, L. Bubendorf, P. Bunn, T. Cascone, J. Chaft, Gang Chen, T. Chou, W. Cooper, J. Erasmus, C. Ferreira, J. Goo, J. Heymach, F. Hirsch, H. Horinouchi, K. Kerr, M. Kris, D. Jain, Y. T. Kim, F. López-Rios, Shun Lu, T. Mitsudomi, A. Moreira, N. Motoi, A. Nicholson, R. Oliveira, M. Papotti, U. Pastorino, L. Paz-Ares, G. Pelosi, C. Poleri, M. Provencio, A. Roden, G. Scagliotti, S. Swisher, E. Thunnissen, M. Tsao, J. Vansteenkiste, W. Weder, Y. Yatabe   +42 more
semanticscholar   +1 more source

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives

Biomarker Research, 2023
Over the past decade, targeted therapy for oncogene-driven NSCLC and immune checkpoint inhibitors for non-oncogene-driven NSCLC, respectively, have greatly improved the survival and quality of life for patients with unresectable NSCLC.
Luis A. Godoy, Joy Y. Chen, Weijie Ma, Jag Lally, K. Toomey, P. Rajappa, R. Sheridan, Shirish Mahajan, N. Stollenwerk, C. Phan, D. Cheng, R. Knebel, Tianhong Li   +12 more
semanticscholar   +1 more source

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. [PDF]

, 2019
Dedicated breast positron emission tomography (dbPET) is an emerging technology with high sensitivity and spatial resolution that enables detection of sub-centimeter lesions and depiction of intratumoral heterogeneity.
Chien, Amy J, Esserman, Laura J, Franc, Benjamin L, Hylton, Nola M, Joe, Bonnie N, Jones, Ella F, Li, Wen, Mukhtar, Rita A, Pampaloni, Miguel H, Ray, Kimberly M, Seo, Youngho   +10 more
core   +2 more sources

Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy

Bioactive Materials, 2023
Surgical resection remains a mainstay in the treatment of malignant solid tumors. However, the use of neoadjuvant treatments, including chemotherapy, radiotherapy, phototherapy, and immunotherapy, either alone or in combination, as a preoperative ...
Xiaogang Qu, Dong Zhou, Jianpu Lu, Duotian Qin, Jun Zhou, Hai-Jun Liu   +5 more
doaj   +1 more source

Real-world analysis of leuprorelin acetate microspheres-based neoadjuvant therapy for patients with high-risk prostate cancer

Frontiers in Oncology
ObjectiveBoennuokang® leuprorelin acetate microspheres show a certain efficacy in patients with prostate cancer, but its utilization as neoadjuvant therapy in patients with high-risk prostate cancer remains unclear.
Changde Fu, Jun Xin, Jinjin Lai, Xu Zeng, Yongnan Wang, Wei Zhang   +5 more
doaj   +1 more source

An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer

Frontiers in Oncology, 2023
BackgroundThis open, observational clinical study aimed to investigate the efficacy, safety and survival outcomes of neoadjuvant chemotherapy, neoadjuvant immunotherapy with(out) chemotherapy and neoadjuvant targeted therapy among resectable stage III ...
Yuwen Qi, Linping Gu, Jie Shen, Yaxian Yao, Yi Zhao, Shun Lu, Zhiwei Chen   +6 more
doaj   +1 more source

Treatment of Locally Advanced Rectal Cancer in the Era of Total Neoadjuvant Therapy

JAMA Network Open
Key Points Question Which neoadjuvant regimen is associated with the highest pathological complete response (pCR) in the treatment of locally advanced rectal cancer?
G. Turri, G. Ostuzzi, Giovanni Vita, Valeria Barresi, A. Scarpa, M. Milella, R. Mazzarotto, A. Ruzzenente, C. Barbui, C. Pedrazzani   +9 more
semanticscholar   +1 more source

Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials

Therapeutic Advances in Medical Oncology, 2022
The treatment of malignant melanoma has drastically changed over the past decade with the advent of immune checkpoint blockade, targeted therapy with BRAF/MEK inhibition, and other novel therapies such as oncolytic virus intralesional therapy.
R. Witt, Derek J. Erstad, J. Wargo
semanticscholar   +1 more source

Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities [PDF]

, 2017
© 2017 The Author(s). Anti-cancer therapies including chemotherapy aim to induce tumour cell death. Cell death introduces alterations in cell morphology and tissue micro-structures that cause measurable changes in tissue echogenicity.
A Ahmed, A Guimond, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, B Banihashemi, B Fisher, B Ganeshan, BS Garra, BS Pio, BT Hennessy, C-P Chou, D Sethi, DA Mankoff, EJ Feleppa, EJ Feleppa, F Tixier, FJ Esteva, FL Lizzi, FT D’Astous, G Berger, G Minckwitz von, GJ Czarnota, GJ Czarnota, GN Hortobagyi, H Haibo, H Tadayyon, H Tadayyon, H Tadayyon, HC Kim, HM Kuerer, II Wistuba, J Czernin, JB Nikas, JPB O’Connor, K Brindle, K Sikora, K Suzuki, KA Wear, KM Brindle, KN Ogston, L Sannachi, LX Yao, M Dowsett, M Vaidya, MF Insana, ML Oelze, ML Oelze, N Duric, O Falou, O Falou, QH Huang, R Tiling, RM Haralick, RM Vlad, RM Vlad, SH Giordano, SH Giordano, SJ Cleator, SM Scholl, T Cover, TJ Larkin, U McDermott, V Goh, V Guarneri, X Li, Y Labyed   +70 more
core   +2 more sources